This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vascular Solutions Acquires Zerusa Limited And The Guardian® Hemostasis Valves

Vascular Solutions, Inc. (Nasdaq: VASC) today announced that it has acquired the assets of Zerusa Limited, a Galway, Ireland based medical device company engaged in the manufacture and distribution of the Guardian® hemostasis valves. The Guardian hemostasis valves are designed to maintain hemostasis during interventional catheterization procedures through a novel sealing system which allows simple introduction and removal of interventional devices while providing the option to lock guidewires in place.

Vascular Solutions has been selling the Guardian hemostasis valves in the U.S. under an exclusive distribution relationship with Zerusa since 2007. In international markets, Zerusa has been selling the Guardian hemostasis valves through a network of independent distributors. Worldwide sales of the Guardian hemostasis valves were $1.7 million in 2010, consisting of $1.3 million in sales by Vascular Solutions in the U.S. and $0.4 million in sales by Zerusa to distributors for sale in international markets. Effective immediately, international sales of the Guardian products will transition to Vascular Solutions’ existing international distribution network, while U.S. sales will continue to be made through Vascular Solutions’ direct sales force.

To effectuate the acquisition, Vascular Solutions has organized a wholly-owned subsidiary located in Galway, Ireland. The Irish subsidiary employs the three previous employees of Zerusa and will continue to manage the manufacture and development of the Guardian hemostasis valves in Ireland. The acquisition price of €3.15 million ($4.3 million) consists of €2.85 million ($3.9 million) paid at closing and €0.3 million ($0.4 million) payable six months following closing.

“We are excited about acquiring the Guardian hemostasis valves and being able to expand their market exposure while capturing the entire margin on the sale of the products in the U.S. and adding international sales to our results,” commented Howard Root, Chief Executive Officer of Vascular Solutions. “Since we have been selling these products for over three years, we know their position and their potential very well. We also look forward to finalizing device improvements to the Guardian valves and developing additional products with our new Irish employees,” Mr. Root added.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs